Pub Date : 2016-01-08DOI: 10.1080/15321819.2015.1132230
Oluwatosin Akende, O. Akanbi, A. Oluremi, I. Okonko, O. Opaleye
Cytomegalovirus (CMV) is one of the predominant viral infections that lead to congenital diseases and teratogenic risks during the perinatal stage. There is paucity of seroepidemiological data on anti-CMV IgG antibody in pregnant women in Osogbo, Osun State, Nigeria. This study was aimed at determining the seroprevalence of Cytomegalovirus IgG antibody among pregnant women visiting antenatal clinic, LAUTECH Teaching Hospital, Osogbo, Nigeria. One hundred and seventy-four sera from the pregnant women were screened by Enzyme linked Immunosorbent Assay (ELISA) for cytomegalovirus (CMV) IgG antibody. Data analysis was done using SPSS software. In this study, 105 of the 174 pregnant women were seropositive for CMV IgG antibodies giving an antibody prevalence of 60%. There was no association found between CMV IgG seropositivity and the subjects’ demographic characteristics, however, the 60.0% prevalence of CMV-IgG antibody observed amongst pregnant women in this study demands for vaccines and regular testing for the presence of CMV and its related risk factors in antenatal clinic.
{"title":"Prevalence of Cytomegalovirus IgG Antibodies among Pregnant Women Visiting Antenatal Clinic, LAUTECH Teaching Hospital in Osogbo, Osun State, Nigeria","authors":"Oluwatosin Akende, O. Akanbi, A. Oluremi, I. Okonko, O. Opaleye","doi":"10.1080/15321819.2015.1132230","DOIUrl":"https://doi.org/10.1080/15321819.2015.1132230","url":null,"abstract":"Cytomegalovirus (CMV) is one of the predominant viral infections that lead to congenital diseases and teratogenic risks during the perinatal stage. There is paucity of seroepidemiological data on anti-CMV IgG antibody in pregnant women in Osogbo, Osun State, Nigeria. This study was aimed at determining the seroprevalence of Cytomegalovirus IgG antibody among pregnant women visiting antenatal clinic, LAUTECH Teaching Hospital, Osogbo, Nigeria. One hundred and seventy-four sera from the pregnant women were screened by Enzyme linked Immunosorbent Assay (ELISA) for cytomegalovirus (CMV) IgG antibody. Data analysis was done using SPSS software. In this study, 105 of the 174 pregnant women were seropositive for CMV IgG antibodies giving an antibody prevalence of 60%. There was no association found between CMV IgG seropositivity and the subjects’ demographic characteristics, however, the 60.0% prevalence of CMV-IgG antibody observed amongst pregnant women in this study demands for vaccines and regular testing for the presence of CMV and its related risk factors in antenatal clinic.","PeriodicalId":15987,"journal":{"name":"Journal of Immunoassay and Immunochemistry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91450668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-01-08DOI: 10.1080/15321819.2015.1135162
Sang-Ii Ahn, Ji-Soo Kim, Chae-Yeon Hong, Gyo-Jeong Gu, Hyeon-Myeong Shin, H. Jeong, Kwang Oh Koh, J. Mang, Dae Young Kim, H. Youn
Toll-like receptor 4 (TLR4) recognizes LPS and triggers the activation of the myeloid differential factor 88 (MyD88)- and toll-interleukin-1 receptor domain-containing adapter, inducing interferon-β (TRIF)-dependent major downstream signaling pathways. Previously, we presented biochemical evidence that 1-[4-Fluoro-2-(2-nitrovinyl)phenyl]pyrrolidine (FPP), which was synthesized in our laboratory, inhibits NF-κB activation induced by LPS. Here, we investigated whether FPP modulates the TLR4 downstream signaling pathways and what anti-inflammatory target in TLR4 signaling is regulated by FPP. FPP inhibited LPS-induced NF-κB activation by targeting TLR4 dimerization. These results suggest that FPP can modulate the TLR4 signaling pathway at the receptor level to decrease inflammatory gene expression.
{"title":"1-[4-Fluoro-2-(2-nitrovinyl)phenyl]pyrrolidine Suppresses Toll-Like Receptor 4 Dimerization Induced by Lipopolysaccharide","authors":"Sang-Ii Ahn, Ji-Soo Kim, Chae-Yeon Hong, Gyo-Jeong Gu, Hyeon-Myeong Shin, H. Jeong, Kwang Oh Koh, J. Mang, Dae Young Kim, H. Youn","doi":"10.1080/15321819.2015.1135162","DOIUrl":"https://doi.org/10.1080/15321819.2015.1135162","url":null,"abstract":"Toll-like receptor 4 (TLR4) recognizes LPS and triggers the activation of the myeloid differential factor 88 (MyD88)- and toll-interleukin-1 receptor domain-containing adapter, inducing interferon-β (TRIF)-dependent major downstream signaling pathways. Previously, we presented biochemical evidence that 1-[4-Fluoro-2-(2-nitrovinyl)phenyl]pyrrolidine (FPP), which was synthesized in our laboratory, inhibits NF-κB activation induced by LPS. Here, we investigated whether FPP modulates the TLR4 downstream signaling pathways and what anti-inflammatory target in TLR4 signaling is regulated by FPP. FPP inhibited LPS-induced NF-κB activation by targeting TLR4 dimerization. These results suggest that FPP can modulate the TLR4 signaling pathway at the receptor level to decrease inflammatory gene expression.","PeriodicalId":15987,"journal":{"name":"Journal of Immunoassay and Immunochemistry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88417579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-01-08DOI: 10.1080/15321819.2015.1135163
A. Attallah, M. El-Far, M. Omran, K. Farid, Ahmed A Attallah, Dalal Abd-Elaziz, M. Elbendary, I. El‐Dosoky, H. Ismail
The goal of this study was to determine the levels of S. mansoni antigen in different liver fibrosis stages with chronic hepatitis C (CHC) Egyptian patients. A total of 174 CHC patients showing HCV-NS4 antigen and HCV- RNA in their sera were included. S. mansoni antigen was detected in serum using Western blot and ELISA. The levels of interferon-γ (IFN- γ) were determined using ELISA. The 50 kDa S. mansoni antigen discriminated patients infected with S. mansoni from healthy individuals with 0.93 area under curve (AUC), 92% sensitivity, and 97% specificity. The level of S. mansoni antigen (μg/ml) was significantly (P < 0.0001) increased with the progression of liver fibrosis stages (26.9 ± 17.5 in F1, 42.1 ± 25.2 in F2, 49.8 ± 30.3 in F3 and 62.2 ± 26.3 μg/mL in F4 liver cirrhosis), 26.9 ± 17.59 in significant fibrosis (F2–F4); 51.2 ± 27.9 in advanced fibrosis (F3–F4). A significant correlation (r = 0.506; P < 0.0001) was shown between the levels of the S. mansoni antigen and the HCV-NS4 antigen. In conclusion, the presence of S. mansoni antigen in different liver fibrosis stages of CHC patients confirming that concomitant schistosome infection aggravates liver disease.
{"title":"Levels of Schistosoma mansoni Circulating Antigen in Chronic Hepatitis C Patients with Different Stages of Liver Fibrosis","authors":"A. Attallah, M. El-Far, M. Omran, K. Farid, Ahmed A Attallah, Dalal Abd-Elaziz, M. Elbendary, I. El‐Dosoky, H. Ismail","doi":"10.1080/15321819.2015.1135163","DOIUrl":"https://doi.org/10.1080/15321819.2015.1135163","url":null,"abstract":"The goal of this study was to determine the levels of S. mansoni antigen in different liver fibrosis stages with chronic hepatitis C (CHC) Egyptian patients. A total of 174 CHC patients showing HCV-NS4 antigen and HCV- RNA in their sera were included. S. mansoni antigen was detected in serum using Western blot and ELISA. The levels of interferon-γ (IFN- γ) were determined using ELISA. The 50 kDa S. mansoni antigen discriminated patients infected with S. mansoni from healthy individuals with 0.93 area under curve (AUC), 92% sensitivity, and 97% specificity. The level of S. mansoni antigen (μg/ml) was significantly (P < 0.0001) increased with the progression of liver fibrosis stages (26.9 ± 17.5 in F1, 42.1 ± 25.2 in F2, 49.8 ± 30.3 in F3 and 62.2 ± 26.3 μg/mL in F4 liver cirrhosis), 26.9 ± 17.59 in significant fibrosis (F2–F4); 51.2 ± 27.9 in advanced fibrosis (F3–F4). A significant correlation (r = 0.506; P < 0.0001) was shown between the levels of the S. mansoni antigen and the HCV-NS4 antigen. In conclusion, the presence of S. mansoni antigen in different liver fibrosis stages of CHC patients confirming that concomitant schistosome infection aggravates liver disease.","PeriodicalId":15987,"journal":{"name":"Journal of Immunoassay and Immunochemistry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87750731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-01-02DOI: 10.1080/15321819.2015.1116009
C. Tanase, R. Albulescu, M. Neagu
Proteomic technologies remain the main backbone of biomarkers discovery in cancer. The continuous development of proteomic technologies also enlarges the bioinformatics domain, thus founding the main pillars of cancer therapy. The main source for diagnostic/prognostic/therapy monitoring biomarker panels are molecules that have a dual role, being both indicators of disease development and therapy targets. Proteomic technologies, such as mass-spectrometry approaches and protein array technologies, represent the main technologies that can depict these biomarkers. Herein, we will illustrate some of the most recent strategies for biomarker discovery in cancer, including the development of immune-markers and the use of cancer stem cells as target therapy. The challenges of proteomic biomarker discovery need new forms of cross-disciplinary conglomerates that will result in increased and tailored access to treatments for patients; diagnostic companies would benefit from the enhanced co-development of companion diagnostics and pharmaceutical companies. In the technology optimization in biomarkers, immune assays are the leaders of discovery machinery.
{"title":"Proteomic Approaches for Biomarker Panels in Cancer","authors":"C. Tanase, R. Albulescu, M. Neagu","doi":"10.1080/15321819.2015.1116009","DOIUrl":"https://doi.org/10.1080/15321819.2015.1116009","url":null,"abstract":"Proteomic technologies remain the main backbone of biomarkers discovery in cancer. The continuous development of proteomic technologies also enlarges the bioinformatics domain, thus founding the main pillars of cancer therapy. The main source for diagnostic/prognostic/therapy monitoring biomarker panels are molecules that have a dual role, being both indicators of disease development and therapy targets. Proteomic technologies, such as mass-spectrometry approaches and protein array technologies, represent the main technologies that can depict these biomarkers. Herein, we will illustrate some of the most recent strategies for biomarker discovery in cancer, including the development of immune-markers and the use of cancer stem cells as target therapy. The challenges of proteomic biomarker discovery need new forms of cross-disciplinary conglomerates that will result in increased and tailored access to treatments for patients; diagnostic companies would benefit from the enhanced co-development of companion diagnostics and pharmaceutical companies. In the technology optimization in biomarkers, immune assays are the leaders of discovery machinery.","PeriodicalId":15987,"journal":{"name":"Journal of Immunoassay and Immunochemistry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88201695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-01-01DOI: 10.1080/15321819.2016.1162800
Navneet Kaur, B V Sunil Kumar, Kanika Mahajan, Satparkash Singh
All four members of the tissue inhibitors of metalloproteinase (TIMP) family have been reported to be over-expressed in breast cancer cells in vitro. Dysregulation of TIMP-4 expression predicts poor prognosis in cancers. The present study evaluated the association of the expression levels of TIMP-4 with mammary tumor development in dogs, measured by real-time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Mammary tissue samples were collected from healthy canine mammary gland and from tumor subjects. TIMP-4 expression was found to be upregulated (5.856 times) in complex canine mammary carcinomas. Also, TIMP-4 mature peptide was expressed heterologously in E. coli. The recombinant protein was purified by Ni- NTA affinity chromatography and further confirmed by western blotting. The rTIMP-4 was found to be functionally active and could inhibit matrix metalloproteinase 11(MMP-11) activity. Immunization of mice with rTIMP-4 resulted in increased antigen specific serum antibody titer, and this serum could be suitably used to detect and quantify the protein in sera of dogs with mammary tumors. TIMP-4 could act as a marker of canine mammary tumors. To the best of our knowledge, this is the first report of heterologous expression of TIMP-4 from complex canine mammary carcinomas.
据报道，组织金属蛋白酶抑制剂（TIMP）家族的所有四个成员都在体外乳腺癌细胞中过度表达。TIMP-4 表达失调预示着癌症的不良预后。本研究通过实时定量逆转录酶聚合酶链反应（qRT-PCR）测定了 TIMP-4 的表达水平与狗乳腺肿瘤发生的关系。乳腺组织样本采集自健康犬乳腺和肿瘤受试者。结果发现，在复杂犬乳腺癌中，TIMP-4 表达上调（5.856 倍）。此外，还在大肠杆菌中异源表达了 TIMP-4 成熟肽。重组蛋白通过 Ni- NTA 亲和层析法纯化，并进一步通过 Western 印迹法确认。研究发现rTIMP-4具有功能活性，能抑制基质金属蛋白酶11（MMP-11）的活性。用rTIMP-4免疫小鼠可提高抗原特异性血清抗体滴度，该血清可用于检测和定量乳腺肿瘤犬血清中的该蛋白。TIMP-4 可作为犬乳腺肿瘤的标记物。据我们所知，这是首次报道复杂犬乳腺癌异源表达 TIMP-4。
{"title":"Expression and characterization of tissue inhibitor of metalloproteinase 4 from complex canine mammary carcinomas.","authors":"Navneet Kaur, B V Sunil Kumar, Kanika Mahajan, Satparkash Singh","doi":"10.1080/15321819.2016.1162800","DOIUrl":"10.1080/15321819.2016.1162800","url":null,"abstract":"<p><p>All four members of the tissue inhibitors of metalloproteinase (TIMP) family have been reported to be over-expressed in breast cancer cells in vitro. Dysregulation of TIMP-4 expression predicts poor prognosis in cancers. The present study evaluated the association of the expression levels of TIMP-4 with mammary tumor development in dogs, measured by real-time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Mammary tissue samples were collected from healthy canine mammary gland and from tumor subjects. TIMP-4 expression was found to be upregulated (5.856 times) in complex canine mammary carcinomas. Also, TIMP-4 mature peptide was expressed heterologously in E. coli. The recombinant protein was purified by Ni- NTA affinity chromatography and further confirmed by western blotting. The rTIMP-4 was found to be functionally active and could inhibit matrix metalloproteinase 11(MMP-11) activity. Immunization of mice with rTIMP-4 resulted in increased antigen specific serum antibody titer, and this serum could be suitably used to detect and quantify the protein in sera of dogs with mammary tumors. TIMP-4 could act as a marker of canine mammary tumors. To the best of our knowledge, this is the first report of heterologous expression of TIMP-4 from complex canine mammary carcinomas. </p>","PeriodicalId":15987,"journal":{"name":"Journal of Immunoassay and Immunochemistry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/15321819.2016.1162800","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83735376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-10-02DOI: 10.1080/15321819.2014.895643
{"title":"Ed Board EOV","authors":"","doi":"10.1080/15321819.2014.895643","DOIUrl":"https://doi.org/10.1080/15321819.2014.895643","url":null,"abstract":"","PeriodicalId":15987,"journal":{"name":"Journal of Immunoassay and Immunochemistry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81538093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-10-02DOI: 10.1080/15321819.2013.802887
{"title":"Editorial Board EOV","authors":"","doi":"10.1080/15321819.2013.802887","DOIUrl":"https://doi.org/10.1080/15321819.2013.802887","url":null,"abstract":"","PeriodicalId":15987,"journal":{"name":"Journal of Immunoassay and Immunochemistry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75493467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-10-01DOI: 10.1080/15321819.2012.721977
{"title":"Editorial Board EOV","authors":"","doi":"10.1080/15321819.2012.721977","DOIUrl":"https://doi.org/10.1080/15321819.2012.721977","url":null,"abstract":"","PeriodicalId":15987,"journal":{"name":"Journal of Immunoassay and Immunochemistry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76224100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-06-02DOI: 10.1080/15321810802122103
L. Hirnle, I. Kątnik-Prastowska
Abstract The relative expression of the EDA region in fibronectin (FN) was determined by ELISA, using specific monoclonal antibody anti-EDA-FN, in the amniotic fluid samples derived from: 2nd trimester, early 3rd trimester, term, and post-term pregnancy, delivery at 37–40 weeks and at 41–42 weeks, as well as pregnancies complicated by fetal postmaturity. The expression of EDA-FN isoform was almost on the same level from the 2nd trimester to the 3rd trimester including term and post-term pregnancy. However, its relative amount significantly decreased in delivery groups and was significantly higher in the pregnancies with fetal postmaturity syndrome.
{"title":"EDA Fibronectin Isoform of Amniotic Fluid in Relation to Normal Pregnancy Stages and to Pregnancies Complicated by Fetal Postmaturity Syndrome","authors":"L. Hirnle, I. Kątnik-Prastowska","doi":"10.1080/15321810802122103","DOIUrl":"https://doi.org/10.1080/15321810802122103","url":null,"abstract":"Abstract The relative expression of the EDA region in fibronectin (FN) was determined by ELISA, using specific monoclonal antibody anti-EDA-FN, in the amniotic fluid samples derived from: 2nd trimester, early 3rd trimester, term, and post-term pregnancy, delivery at 37–40 weeks and at 41–42 weeks, as well as pregnancies complicated by fetal postmaturity. The expression of EDA-FN isoform was almost on the same level from the 2nd trimester to the 3rd trimester including term and post-term pregnancy. However, its relative amount significantly decreased in delivery groups and was significantly higher in the pregnancies with fetal postmaturity syndrome.","PeriodicalId":15987,"journal":{"name":"Journal of Immunoassay and Immunochemistry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79801789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2006-12-01DOI: 10.1080/15321810600862389
J. Kutter
Separation Methods in Microanalytical Systems is a well designed, organized, and written book which deals with a timely topic. In the last couple of decades scientists started talking about miniaturization of analytical instrumentation and lab-on-a-chip. This book concerns itself with certain aspects of microfluidics – the behavior of fluids in confined spaces and the manipulation of these fluids – namely, the possibility to perform chemical analyses, biochemical assays, and similar processes. The products of this kind of research are often dubbed micro-Total Analysis Systems (m-TAS) or, more generally, lab-on-a-chip (LOC) devices. As it is intended for a wide audience, it was also written by contributors from many of the disciplines that constitute the backbone of the LOC community. Of course, this book cannot attempt to cover the entire field of LOC. Instead it focuses on what has been one of the main driving forces behind the development of LOC for the last 15 years: miniaturized separation systems. Separation units are still at the heart of many micro-TAS and LOC devices, and modern separation techniques are indispensable tools for analytical chemists. This book gives an overview of separation techniques on micro-fabricated devices: theoretical background information, design and understanding, fabrication and material issues, implementations, and separation systems in relation to other parts of LOC applications (sample preparation, detection, etc.). It is intended as a one-stop shopping guide for questions concerning separation techniques in microanalytical devices. It is, however, not so much meant only as a quick reference guide, but rather as a place to linger and browse. It is very likely that the information is provided in several locations within the book. A multiauthor volume gives the reader different styles, different approaches, and different opinions. Many topics are so common that they reappear in different chapters, showing different angles to approach a given problem, reflecting the different backgrounds from which researchers attach the same issues. This excellent volume makes a good reference for all those interested in microfludics and can be a text for a graduate course. Journal of Immunoassay & Immunochemistry, 27: 379–386, 2006 Copyright # Taylor & Francis Group, LLC ISSN 1532-1819 print/1532-4230 online DOI: 10.1080/15321810600862389
在微分析系统的分离方法是一个精心设计的，有组织的，并写的书，处理及时的主题。在过去的几十年里，科学家们开始讨论分析仪器和芯片实验室的小型化。本书关注微流体的某些方面-流体在密闭空间中的行为和对这些流体的操纵-即，进行化学分析，生化分析和类似过程的可能性。这类研究的产品通常被称为微型全分析系统(m-TAS)，或者更一般地称为芯片上的实验室(LOC)设备。由于它面向广泛的读者，它也是由许多学科的贡献者编写的，这些学科构成了LOC社区的骨干。当然，本书不可能试图涵盖LOC的整个领域。相反，它关注的是过去15年来LOC发展背后的主要驱动力之一:小型化分离系统。分离单元仍然是许多微型tas和LOC设备的核心，现代分离技术是分析化学家不可或缺的工具。本书概述了微制造设备的分离技术:理论背景信息，设计和理解，制造和材料问题，实现，以及与LOC应用(样品制备，检测等)的其他部分相关的分离系统。它的目的是作为一个一站式购物指南的问题，有关分离技术的微量分析设备。然而，它不仅仅是一个快速的参考指南，而是一个逗留和浏览的地方。这些信息很可能是在书中的几个地方提供的。一个多作者的卷给读者不同的风格，不同的方法，和不同的意见。许多主题是如此普遍，以至于它们在不同的章节中反复出现，展示了处理给定问题的不同角度，反映了研究人员对相同问题的不同背景。这个优秀的卷使所有那些感兴趣的微流体一个很好的参考，可以是一个研究生课程的文本。版权# Taylor & Francis Group, LLC ISSN 1532-1819 print/1532-4230 online DOI: 10.1080/15321810600862389
{"title":"The Book Corner","authors":"J. Kutter","doi":"10.1080/15321810600862389","DOIUrl":"https://doi.org/10.1080/15321810600862389","url":null,"abstract":"Separation Methods in Microanalytical Systems is a well designed, organized, and written book which deals with a timely topic. In the last couple of decades scientists started talking about miniaturization of analytical instrumentation and lab-on-a-chip. This book concerns itself with certain aspects of microfluidics – the behavior of fluids in confined spaces and the manipulation of these fluids – namely, the possibility to perform chemical analyses, biochemical assays, and similar processes. The products of this kind of research are often dubbed micro-Total Analysis Systems (m-TAS) or, more generally, lab-on-a-chip (LOC) devices. As it is intended for a wide audience, it was also written by contributors from many of the disciplines that constitute the backbone of the LOC community. Of course, this book cannot attempt to cover the entire field of LOC. Instead it focuses on what has been one of the main driving forces behind the development of LOC for the last 15 years: miniaturized separation systems. Separation units are still at the heart of many micro-TAS and LOC devices, and modern separation techniques are indispensable tools for analytical chemists. This book gives an overview of separation techniques on micro-fabricated devices: theoretical background information, design and understanding, fabrication and material issues, implementations, and separation systems in relation to other parts of LOC applications (sample preparation, detection, etc.). It is intended as a one-stop shopping guide for questions concerning separation techniques in microanalytical devices. It is, however, not so much meant only as a quick reference guide, but rather as a place to linger and browse. It is very likely that the information is provided in several locations within the book. A multiauthor volume gives the reader different styles, different approaches, and different opinions. Many topics are so common that they reappear in different chapters, showing different angles to approach a given problem, reflecting the different backgrounds from which researchers attach the same issues. This excellent volume makes a good reference for all those interested in microfludics and can be a text for a graduate course. Journal of Immunoassay & Immunochemistry, 27: 379–386, 2006 Copyright # Taylor & Francis Group, LLC ISSN 1532-1819 print/1532-4230 online DOI: 10.1080/15321810600862389","PeriodicalId":15987,"journal":{"name":"Journal of Immunoassay and Immunochemistry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83440050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：